Janice Nord, MD
Internal Medicine · Port Charlotte, FLNPI 1063452100
Payments from drug & device makers
Across 186 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$705
- AbbVie$594
- Pfizer$396
- Novo Nordisk$276
- Lilly USA, LLC$184
- GSK$174
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$251%
- Food & beverage$3,55599%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 18 | $705 |
| AbbVie(2 entities) | 32 | $594 |
| Pfizer | 26 | $396 |
| Novo Nordisk | 17 | $276 |
| Lilly USA, LLC | 11 | $184 |
| GSK | 12 | $174 |
| Merck | 11 | $161 |
| GE HealthCare | 11 | $150 |
| Boston Scientific | 4 | $133 |
| AstraZeneca | 7 | $88 |
| Intuitive Surgical | 1 | $85 |
| Astellas Pharma US Inc | 4 | $81 |
| Sanofi-aventis U.S. LLC | 3 | $79 |
| Amgen | 6 | $78 |
| Amarin Pharma, Inc. | 3 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Novartis | 4 | $53 |
| Radius Health, Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $33 |
| Eisai Inc. | 1 | $33 |
| Mannkind Corporation | 1 | $19 |
| Abiomed | 1 | $18 |
| Duchesnay USA Incorporated | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$334
How this compares
$3,580 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $117,432 |
| OzempicSemaglutide | 64 | $74,305 |
| ProliaDenosumab | 39 | $69,160 |
| FarxigaDapagliflozin Propanediol | 22 | $35,415 |
| JardianceEmpagliflozin | 20 | $33,638 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $32,489 |
| TrulicityDulaglutide | 23 | $23,484 |
| XareltoRivaroxaban | 11 | $18,170 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,154 |
| MyrbetriqMirabegron | 14 | $12,988 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $11,981 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $9,671 |
| Atorvastatin Calcium | 891 | $6,707 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $6,062 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $396 | $118,861131 claims |
| Novo NordiskOzempic | $276 | $74,30564 claims |
| AmgenProlia | $78 | $69,16039 claims |
| AstraZenecaFarxiga, Symbicort | $88 | $47,39653 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $174 | $45,64369 claims |
| Boehringer IngelheimJardiance | $33 | $33,63820 claims |
| Lilly USA, LLCTrulicity | $184 | $23,48423 claims |
| Johnson & JohnsonXarelto | $705 | $18,17011 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $12,98814 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $12 | $3,84511 claims |
| AbbVieSynthroid | $594 | $3,81670 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Port Charlotte
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.